Abstract
The JN1 variant harbors Leu455Ser and three mutations in non-spike
proteins contributing to increased transmissibility and immune escape
ability, also pseudovirus assay showed that the infectivity of JN.1 was
significantly higher than its predecessor (1). JN.1 is about 3 to 5
times less susceptible to neutralizing antibodies than the XBB.1.5
variant that is in the updated booster raising concerns about its
potential impact on public health (2) Recent data indicates a
significant rise in cases associated with this variant, underscoring the
need for immediate action. The antiviral Paxlovid, Remdesivir, and
Molnupiravir continue to show activity against XBB-derived and BA.2.86
variants, suggesting that the current therapeutic tools remain
effective(3).